Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) Target Price at $16.00

Coya Therapeutics, Inc. (NASDAQ:COYA) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $16.00.

COYA has been the subject of a number of recent analyst reports. D. Boral Capital restated a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a report on Monday, March 16th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, March 23rd.

Coya Therapeutics Trading Down 4.5%

Shares of COYA opened at $3.78 on Tuesday. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75. The firm has a market capitalization of $88.68 million, a P/E ratio of -2.98 and a beta of 0.23. The firm has a 50-day moving average price of $4.65 and a 200 day moving average price of $5.42.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The firm had revenue of $3.96 million for the quarter, compared to analysts’ expectations of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%. Equities research analysts predict that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in shares of Coya Therapeutics during the third quarter valued at about $28,000. CIBC Private Wealth Group LLC acquired a new position in shares of Coya Therapeutics in the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP purchased a new position in shares of Coya Therapeutics during the 4th quarter worth approximately $66,000. Lantern Wealth Advisors LLC purchased a new position in shares of Coya Therapeutics during the 3rd quarter worth approximately $66,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in Coya Therapeutics in the 4th quarter valued at approximately $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.